DexCom (DXCM) Stock Forecast & Price Target

$75.24 +0.36 (+0.48%)

(As of 11/20/2024 ET)

DexCom - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
6

Buy
12

Based on 18 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for DXCM.

Consensus Price Target

$104.59
39.01% Upside

According to the 18 analysts' twelve-month price targets for DexCom, the average price target is $104.59. The highest price target for DXCM is $161.00, while the lowest price target for DXCM is $75.00. The average price target represents a forecasted upside of 39.01% from the current price of $75.24.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

DXCM Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$104.59	$110.73	$112.25	$130.93
Forecasted Upside	39.01% Upside	51.52% Upside	51.55% Upside	18.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Medical Companies	S&P 500
Consensus Rating Score	2.72	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	39.01% Upside	26,906.41% Upside	9.81% Upside
News Sentiment Rating	Positive News See Recent DXCM News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/25/2024	Sanford C. Bernstein 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$82.00 ➝ $86.00	+16.55%
10/25/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$120.00 ➝ $115.00	+53.54%
10/25/2024	Raymond James 4 of 5 stars		Lower Target	Strong-Buy ➝ Strong-Buy	$115.00 ➝ $99.00	+32.18%
10/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$115.00 ➝ $105.00	+39.55%
10/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$75.00 ➝ $85.00	+15.66%
10/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $87.00	+19.10%
Get the Latest News and Ratings for DXCM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.
10/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$80.00 ➝ $90.00	+20.24%
8/26/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+20.74%
8/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+38.35%
8/5/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$80.00 ➝ $82.00	+13.42%
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$138.00 ➝ $113.00	+67.33%
7/26/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$156.00 ➝ $120.00	+88.62%
7/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$120.00 ➝ $75.00	+19.73%
7/26/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$163.00 ➝ $95.00	+49.42%
7/23/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $145.00	+29.87%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$130.00	+1.85%
4/3/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$148.00 ➝ $161.00	+15.86%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$114.00 ➝ $125.00	+16.56%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$121.00	+16.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:21 AM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

DexCom's stock is currently trading at a lower price, presenting a potential buying opportunity for investors looking to enter at a favorable price point.
The company has a strong market capitalization of $27.66 billion, indicating stability and potential for growth in the future.
Institutional investors and hedge funds own a significant portion (97.75%) of DexCom's stock, reflecting confidence from large financial entities in the company's performance.
DexCom's continuous glucose monitoring (CGM) systems cater to a growing market of people with diabetes, showcasing a product line with high demand and relevance in the healthcare industry.
Despite recent insider selling, the overall sentiment from analysts is positive with an average rating of "Moderate Buy" and an average target price of $110.69, suggesting potential upside for investors.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

Recent insider selling activities by executive vice presidents may raise concerns about the company's future performance or internal outlook.
The stock's price-to-earnings ratio of 44.79 and a P/E/G ratio of 2.16 may indicate that the stock is currently overvalued compared to its growth prospects, potentially limiting short-term gains.
DexCom's stock has experienced a significant decrease from its 1-year high of $142.00, suggesting potential volatility and uncertainty in the stock's performance.
The company's debt-to-equity ratio of 1.00 may pose risks in terms of financial leverage and debt management, impacting long-term financial stability.
The stock's 50-day moving average price of $70.25 is below its two-hundred day moving average price of $103.61, indicating a potential bearish trend in the stock's performance.

DXCM Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $104.59, with a high forecast of $161.00 and a low forecast of $75.00.
: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares.
: According to analysts, DexCom's stock has a predicted upside of 39.01% based on their 12-month stock forecasts.
: DexCom has been rated by research analysts at JPMorgan Chase & Co., Leerink Partners, Oppenheimer, Piper Sandler, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.
: Analysts like DexCom less than other "medical" companies. The consensus rating score for DexCom is 2.72 while the average consensus rating score for "medical" companies is 2.80. Learn more on how DXCM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

This page (NASDAQ:DXCM) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Stock Forecast & Price Target